In Vitro Lung Model Market Size & Growth Forecast 2026–2035, By Segments (Type, End-use, Application), Regional Demand Trends (North America, Asia Pacific, Europe), Key Country Insights (U.S., Japan, South Korea, Germany, France, Italy), and Competitive Landscape
Market Size and Growoth Outlook
In Vitro Lung Model Market size was more than USD 408.65 Million in 2025 and is set to grow at a 17.3% CAGR between 2026 and 2035, attaining USD 2.02 Billion by 2035. The industry revenue for 2026 is calculated at USD 471.56 million.
Get more details on this report
Request Free Sample ReportIn Vitro Lung Model Market Intelligence Snapshot
Regional Market Dynamics
- North America held a 46.95% market share in 2025, supported by extensive pharmaceutical and biotechnology research, established laboratory infrastructure, and routine adoption of advanced lung models in drug development.
- Europe is projected to grow at a 19.38% CAGR as biomedical researchers, academic institutes, CROs, and life sciences companies increasingly adopt physiologically relevant lung models for testing and screening.
Segment Momentum
- 2D models lead with a 59.66% share due to strong integration in routine lab workflows, established experimental protocols, and cost-effective, high-throughput screening suitability in early-stage research environments.
- 3D models are growing fastest as researchers prioritize physiologically relevant systems that better replicate lung tissue structure and cellular interactions, improving predictive accuracy in experimental outcomes.
Market Expansion Drivers
- Rising prevalence of COPD, asthma, and lung cancer driving respiratory disease modeling demand.
- Shift toward animal testing alternatives accelerating adoption of advanced in vitro respiratory models.
- Advancements in 3D cell culture and iPSC-based lung systems improving disease simulation accuracy.
Leading Market Participants
Global Market Forecast Snapshot
Market Outlook
Prominent companies in the in vitro lung model market include Lonza Group AG (Switzerland), Emulate, Inc. (United States), MatTek Corporation (United States), MIMETAS B.V. (Netherlands), Epithelix Sàrl (Switzerland), InSphero AG (Switzerland), AlveoliX AG (Switzerland), CN Bio Innovations Ltd. (United Kingdom), TissUse GmbH (Germany), ATCC (United States).Regional and Segment Outlook
North AmericaMarket Growth Drivers and Industry Trends
As respiratory disorders account for a larger share of pharmaceutical and translational research activity, developers are investing more heavily in tools that can reproduce diseased airway and alveolar biology with greater fidelity. The in vitro lung model market benefits from this shift because COPD, asthma, and lung cancer programs require repeatable systems for studying inflammation, tissue remodeling, mucus response, tumor behavior, and drug permeability before moving into costly later-stage work. In practice, rising disease burden pushes biopharma companies, academic centers, and contract research organizations to expand respiratory screening pipelines, which reinforces market demand for lung-specific models that can support target validation, toxicity assessment, and compound prioritization under clinically relevant conditions.
Shift toward animal testing alternatives accelerating adoption of advanced in vitro respiratory models
Pressure to reduce reliance on animal studies is changing how respiratory research is designed, especially in early discovery and safety assessment where human-relevant data is increasingly valued. That dynamic is strengthening market development in the in vitro lung model market because advanced airway and lung tissue platforms offer a practical route to evaluate inhaled compounds, toxic exposures, and disease mechanisms without the translational limitations that often affect animal respiratory models. Procurement decisions are moving toward systems that can generate standardized, reproducible readouts for regulatory documentation and internal R&D go/no-go decisions, increasing market penetration for organotypic and microphysiological lung models that fit these newer testing strategies.
Advancements in 3D cell culture and iPSC-based lung systems improving disease simulation accuracy
Improved 3D culture architectures and iPSC-derived lung cell systems are making it possible to capture cell–cell interactions, tissue organization, and patient-linked disease traits more effectively than conventional 2D approaches. This is influencing market adoption in the in vitro lung model market by giving researchers more confidence that preclinical findings will reflect real respiratory biology, especially in studies involving chronic inflammation, fibrosis pathways, infection response, and personalized therapeutic screening. As these platforms become better at reproducing complex lung microenvironments and specific pathological states, buyers are shifting spending toward higher-value models that support mechanistic research and more selective candidate advancement.
| Growth Driver | Impact on CAGR | Regulatory Influence | Geographic Relevance | Adoption Rate | Impact Timeline |
|---|---|---|---|---|---|
| Rising prevalence of COPD, asthma, and lung cancer driving respiratory disease modeling demand | 2.40% | High | North America, Europe | High | Near Term |
| Shift toward animal testing alternatives accelerating adoption of advanced in vitro respiratory models | 2.20% | High | Europe, North America | High | Near Term |
| Advancements in 3D cell culture and iPSC-based lung systems improving disease simulation accuracy | 1.80% | Moderate | North America, Europe, Asia Pacific | Medium | Mid Term |
Unlock insights tailored to your business with our bespoke market research solutions.
Click to get your customized report now.
Regional Demand Dynamics
North America held the leading regional position in 2025, accounting for a 46.95% share of the in vitro lung model market. This leadership is underpinned by the region’s strong concentration of pharmaceutical and biotechnology research activity, where in vitro lung models are used extensively in preclinical testing, toxicology assessment, and respiratory disease research. Demand is further strengthened by established laboratory infrastructure and steady integration of advanced cell-based and tissue-engineered models into drug development workflows, allowing research organizations and manufacturers to adopt these systems more routinely in practical testing environments.
Europe is projected to expand at a 19.38% CAGR over the forecast period in the in vitro lung model market, driven by rising adoption of alternative testing methods across biomedical research and product safety evaluation. Growth is being accelerated by increased use of physiologically relevant lung models in respiratory research, particularly where laboratories seek better translational accuracy than conventional methods can provide. The region’s momentum is also backed by continued uptake across academic institutes, contract research settings, and life sciences companies that are incorporating these models into day-to-day experimentation and screening activities.
| Parameter | North America | Asia Pacific | Europe | Latin America | MEA |
|---|---|---|---|---|---|
| Innovation Hub i Scale Nascent Developing Advanced | |||||
| Cost-Sensitive Region i Scale Low Medium High | |||||
| Regulatory Environment i Scale Restrictive Neutral Supportive | |||||
| Demand Drivers i Scale Weak Moderate Strong | |||||
| Development Stage i Scale Emerging Developing Developed | |||||
| Adoption Rate i Scale Low Medium High | |||||
| New Entrants / Startups i Scale Sparse Moderate Dense | |||||
| Macro Indicators i Scale Weak Stable Strong |
Key Country Insights
Germany 🇩🇪
Precision Testing SolutionsGermany prioritizes highly reproducible in vitro lung models for pharmaceutical research and inhalation safety assessments. Laboratories in Germany continue expanding advanced testing platforms that support regulatory expectations and scientific reliability.
France 🇫🇷
Alternative Testing AdoptionFrance encourages wider use of in vitro lung models to support ethical research practices and advanced respiratory science. Research institutions in France increasingly incorporate these platforms into pharmaceutical and environmental exposure studies.
Italy 🇮🇹
Collaborative Research ExpansionItaly promotes collaborative research using in vitro lung models across universities, healthcare institutions, and life science companies. Growing interest in respiratory disease research encourages broader application of advanced laboratory testing platforms.
Japan 🇯🇵
Translational Research SupportJapan focuses on in vitro lung models that improve translation from laboratory studies to clinical development. Academic and industrial researchers in Japan increasingly utilize physiologically relevant models for respiratory disease investigations.
South Korea 🇰🇷
Biotech Development FocusSouth Korea is strengthening adoption of in vitro lung models through biotechnology research and innovative drug development initiatives. Local organizations increasingly evaluate advanced cell-based systems for respiratory therapeutics and toxicity screening.
United States 🇺🇸
Advanced Research PlatformsThe U.S. invests in sophisticated in vitro lung models supporting respiratory disease research, toxicology, and pharmaceutical development. Research organizations increasingly adopt complex human-relevant models to strengthen preclinical evaluation workflows.
Segment Leadership and Growth Trends
In Vitro Lung Model Market Share (%), Type, 2025
Go beyond the chart, access full insights & data tables
Request Free Sample ReportBy 2025, the 2D Model held a 59.66% share of the in vitro lung model market, reflecting its entrenched role in routine laboratory workflows. its position is maintained through broad usability in early-stage screening, established experimental protocols, and easier integration into existing research setups compared with more complex model formats. For many users in the in vitro lung model market, 2D systems remain the practical choice when consistency, throughput, and operational familiarity are central to study design.
The 3D Model is emerging as the fastest-growing segment in the in vitro lung model market as research needs shift toward more physiologically relevant systems. Growth is being supported by rising demand for models that better reflect lung tissue architecture and cellular interactions than conventional 2D approaches. As study requirements become more focused on biological realism and more predictive in vitro outcomes, 3D Model adoption is accelerating relative to traditional alternatives.
End-use Segment Analysis: Pharmaceutical & Biotechnology Companies (Largest Segment) vs Academic Research Institutes (Fastest-Growing Segment)
In 2025, Pharmaceutical & Biotechnology Companies accounted for the largest share of the in vitro lung model market, supported by their steady use of these systems in drug research and development activities. Their leading position is tied to continuous demand for reproducible in vitro platforms that can support screening, toxicity evaluation, and disease-focused studies within structured development pipelines. This sustained commercial usage keeps Pharmaceutical & Biotechnology Companies at the center of demand in the in vitro lung model market.
Academic Research Institutes represent the fastest-growing end-use segment in the in vitro lung model market as scientific investigation increasingly expands into advanced cellular and tissue-based research applications. Their momentum is encouraged by growing interest in studying lung biology and disease mechanisms through controlled in vitro environments, where more specialized experimental questions are being explored. Compared with commercial users, these institutes are gaining traction through expanding research activity centered on model refinement and exploratory investigation.
| Segment | Sub-Segment | Largest Segment | Fastest Growing |
|---|---|---|---|
| Type | 2D Model, 3D Model | 2D Model | 3D Model |
| End-use | Academic Research Institutes, Pharmaceutical & Biotechnology Companies, Others | Pharmaceutical & Biotechnology Companies | Academic Research Institutes |
| Application | Drug Discovery & Toxicology Studies, Physiological Research, 3D Model Development, Others | Drug Discovery & Toxicology Studies | 3D Model Development |
Competitive Landscape and Market Positioning
1. Lonza Group AG (Switzerland)
2. Emulate Inc. (United States)
3. MatTek Corporation (United States)
4. MIMETAS B.V. (Netherlands)
5. Epithelix Sàrl (Switzerland)
6. InSphero AG (Switzerland)
7. AlveoliX AG (Switzerland)
8. CN Bio Innovations Ltd. (United Kingdom)
9. TissUse GmbH (Germany)
10. ATCC (United States)
The market is advancing through rapid integration of organ-on-chip and microfluidic technologies that improve physiological accuracy of testing models. In the in vitro lung model market, strong research collaboration across scientific ecosystems is accelerating validation of predictive respiratory models. Continuous innovation is reflected in the introduction of more complex 3D cellular structures designed to replicate human lung responses. Regulatory-aligned development practices are also influencing design standards, supporting wider adoption in drug testing and toxicology applications.
| Company | Market Share | Company Revenue | Revenue CAGR (%) | Product Portfolio | Geographic Presence | Innovation / R&D Focus | Strategic Developments |
|---|---|---|---|---|---|---|---|
| No companies available. | |||||||
Industry Development/News
| Company Name | Date | Key Development |
|---|---|---|
| ImmuONE | Nov-23 | ImmuONE raised USD 2.48 million in funding to advance its in vitro lung model platform as an alternative to animal testing in drug discovery. The investment supports expansion of its customer base and continued development of human-relevant respiratory testing models for pharmaceutical and toxicology research applications. |
| CELLINK, MatTek, Visikol | Sep-21 | CELLINK, MatTek, and Visikol launched a collaborative initiative to establish a contract research organization offering integrated bioprinting and advanced tissue modeling services. The partnership combines expertise in 3D bioprinting and tissue engineering to deliver end-to-end solutions for drug testing and in vitro model development. |
| Lonza Group AG and Agilent Technologies | Dec-21 | Lonza Group AG and Agilent Technologies formed a strategic collaboration to integrate advanced analytical technologies with Lonza’s Cocoon platform for cell therapy manufacturing workflows. The partnership enhances process monitoring and analytical integration capabilities, improving scalability and quality control in cell-based therapy production, including respiratory disease applications. |
Explore This Report
Click a section of the wheel — or its numbered marker — to preview the custom segmentation, custom table of contents, or related reports available for this market.
In Vitro Lung Model Market — Custom Segments
| Segment | Sub-Segment |
|---|---|
| No segment data available. | |
In Vitro Lung Model Market — report.custom
| Custom Chapter | Custom Details | ||
|---|---|---|---|
| No custom TOC data available. | |||
Need a different cut of the data?
Request Custom ResearchHow large is the in vitro lung model market?
How will the in vitro lung model industry grow in terms of size and CAGR by 2035?
How is rising respiratory disease burden influencing demand for in vitro lung models?
Why is AI-enabled digital health integration relevant to pediatric hospital market dynamics?
Why do 2D models continue to dominate usage in the in vitro lung model market?
Which segment is driving the fastest growth in the in vitro lung model market?
Why does North America lead the in vitro lung model market?
Why is Europe the fastest-growing region in the in vitro lung model market?
Who holds a significant market share in the in vitro lung model landscape?
Our Clients
"The reports offered a comprehensive view of the Food and Beverage landscape, covering market trends, consumer behavior, and competitive dynamics."
"Our experience in acquiring market research reports has been outstanding — the depth of analysis and actionable insights have proven invaluable."
"Fundamental Business Insights demonstrated a keen understanding of our business needs, delivering reports tailored to our specific objectives."
Our Research Team & Methodology
Every Fundamental Business Insights report is built by a dedicated vertical research team, validated through a structured primary-and-secondary methodology, and reviewed for accuracy before it reaches you.
Research Team Overview
Prepared by the Healthcare & Medical Devices Research Team
Delivery
Published
Demand
Available
Support
Trust & Compliance
Research Domains
10 coverage areasResearch Intelligence
| Source Category | Research Sources | Purpose |
|---|---|---|
| Government Publications | Government agencies, statistical departments, regulatory bodies | Industry statistics, regulatory insights, and policy analysis |
| Company Disclosures | Annual reports, investor presentations, financial filings | Company performance, business strategy, and market positioning |
| Trade Associations | Industry associations and professional organizations | Industry developments, standards, and market perspectives |
| Technical Literature | Research papers, technical publications, academic journals | Technology developments and technical validation |
| Patent Analysis | Patent databases and intellectual property publications | Innovation trends, technology activity, and competitive research |
| Industry Databases | Established research databases and market intelligence resources | Market benchmarking, historical data, and industry analysis |
Research Workflow & Quality Assurance
Data Collection
Verified information gathered through primary and secondary research.
Data Triangulation
Cross-validation using multiple independent data sources.
Forecast Modelling
Market estimates developed using historical trends and analytical models.
Analyst Validation
Findings reviewed by domain experts for accuracy and consistency.
Editorial & Quality Review
Final editorial, quality, and compliance checks before publication.
Final Publication
Released after successful completion of the internal review process.
Report Coverage
📊 Market Assessment
- Market Size & Forecast
- Market Segmentation
- Regional Analysis
- Growth Drivers & Challenges
- Market Dynamics
🏢 Competitive Intelligence
- Competitive Landscape
- Company Profiles
- Competitive Benchmarking
- Mergers & Acquisitions
- Market Share Analysis or Key Company Strategies
🔍 Strategic Analysis
- Value Chain Analysis
- Porter's Five Forces
- PESTLE Analysis
- Pricing Trends
- Supply-Demand Analysis
🚀 Future Outlook
- Technology Landscape
- Regulatory Landscape
- Investment & Funding Landscape
- Emerging Opportunities
- Future Market Outlook
Have a question about this report or need a custom scope?
Request Customization